At meeting held on 03 December 2018
The Board of GlaxoSmithkline Consumer Healthcare at its meeting held on 03 December 2018 approved a scheme of amalgamation between the Company and Hindustan Unilever ('HUL'), and their respective shareholders and creditors ('Scheme') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.The Scheme is subject to necessary statutory and regulatory approvals under applicable laws, including by BSE Limited and National Stock Exchange of India Limited, SEBI, Competition Commission of India, the National Company Law Tribunal, and the respective shareholders and creditors of the Company and HUL.
Powered by Capital Market - Live News